Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI
Pharmaceutical Technology
MAY 18, 2023
An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. It is compatible with standard-of-care antibiotics. Pivotal trials on LMN-201 are expected to commence in 2023.
Let's personalize your content